NCT07370116
Omitting Nasogastric Tube Decompression in Minimally Invasive Pancreaticoduodenectomy
StatusRecruiting
PhaseNot applicable
Primary completion (estimated)
At risk: Primary completion moved at least 8 months later.
See at-risk trials from Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 3 versions: 3 with changes below. See every version on ClinicalTrials.gov ↗
Notable Primary completion pushed from Jul 30, 2026 to Mar 31, 2027 Show 8 more changesShow less
- Phase changed: Phase 2 → Not applicable
- Recruitment opened
- Start date changed from estimate of Apr 1, 2026 to Nov 1, 2026
- Eligibility criteria expanded, about 16 words
- Study completion pushed from Sep 2026 to Jun 30, 2027
- Secondary endpoints: details revised at 1 of 9 entries
- Site details revised
- Collaborators revised (10)
- Notable Start date: Mar 1, 2026 to Apr 1, 2026
- Primary completion date: Jun 30, 2026 to Jul 30, 2026
- Study completion date: Aug 2026 to Sep 2026
- Study First Submitted
- Notable: the plan changed
Endpoints
Primary
Comprehensive Complication Index
Timeframe: 30 days postoperatively
Secondary (9)
pancreaticoduodenectomy-specific complications
abdominal complications
pulmonary complications
comfort
Time to tolerate oral intake (liquids/solids)
Show 4 moreShow less
Hospitalization cost
Mortality rate
Rescue nasogastric tube insertion
Length of stay
Arms and interventions
routine nasogastric tubeActive comparator
standard nasogastric tube placement with the tube retained postoperatively
routine omission of the nasogastric tubeExperimental
avoidance of prophylactic nasogastric tube placement
Procedures: nasogastric tube decompression, Omission of nasogastric tube decompression
Sites
1 site in 1 country
- National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical CollegeBeijing, China